Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non‐alcoholic fatty liver disease

摘要

Abstract Background Aims Long‐term outcomes after percutaneous radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) in patients with non‐alcoholic fatty liver disease (NAFLD) have been poorly studied. We aim to determine the outcomes after multibipolar RFA in these patients compared to other aetiologies as well as the prognostic impact of metabolic syndrome (MS). Methods Patients who underwent multibipolar RFA as the first treatment for HCC within Milan criteria (2008‐2018) were enrolled in this multicentre retrospective cohort from four tertiary centres in France. The association of MS and NAFLD with adverse events and outcomes after percutaneous RFA were assessed using Kaplan Meier method, log‐rank test and uni/multivariate analysis with the Cox models. Results Among 520 patients, 390 patients (75) had at least one component of MS including obesity (30) and 95 had cirrhosis. Sixty‐two patients (12.6) had NAFLD‐HCC, 225?(45.5) had alcohol‐related‐HCC, 36 (7.3) had HBV‐HCC and 171 (34.6) had HCV‐HCC. Patients with NAFLD‐HCC were significantly older (median age 72.6?years, P?